Profiling of desmoid tumors reveals frequent mutations in chromatin-remodeling genes and identifies an Immune-myogenic subtype.

IntroductionDesmoid tumors (DTs) are locally aggressive soft tissue neoplasms with variable clinical behavior and limited therapeutic biomarkers. While CTNNB1 and APC mutations are known, the broader genomic, transcriptomic, and epigenetic features remain incompletely understood.MethodsWe performed integrated genomic, transcriptomic, and DNA methylation profiling on 76 DTs, including post-treatment samples. Targeted gene panel sequencing, RNA-seq, and EPIC methylation arrays were conducted. Molecular subtypes were validated in external cohorts, and immunotherapy response was predicted using immune deconvolution and TIDE analysis.ResultsBeyond canonical CTNNB1/APC mutations, we discovered frequent mutations in chromatin-remodeling genes, notably KMT2C (18%), found in over 50% of samples, including in wild-type tumors. Unsupervised transcriptomic analysis revealed two robust molecular subtypes: immune-myogenic and mesenchymal-like. The immune-myogenic subtype exhibited high expression of myogenic markers, immune checkpoint genes (PDCD1, CD274, CTLA4), tertiary lymphoid structure signatures, and global enhancer hypomethylation linked to interferon and myogenesis pathways. It showed increased infiltration of T, B, and NK cells, higher vascularization, and elevated stemness and epithelial-mesenchymal transition plasticity. TIDE analysis predicted significantly higher ICI responsiveness in the immune-myogenic subtype (58% vs. 26%, p = 0.008), confirmed in an external cohort (69% vs. 10%, p